C. Lawton

发表

Clinically Relevant Changes in Family History of Cancer Over Time

C. Lawton, 2012 .

Long-term risk of colorectal cancer after negative colonoscopy

C. Lawton, 2012 .

Update of Dutch Multicenter Dose-Escalation Trial of Radiotherapy for Localized Prostate Cancer

C. Lawton, 2009 .

Radiation dose–volume effects of the urinary bladder

C. Lawton, 2011 .

Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study

C. Lawton, 2011 .

Hypofractionation for Prostate Cancer

D. Petereit, M. Ritter, J. Forman, 2009, Cancer journal.

Breast Cancer Risk in Female Survivors of Hodgkin'S Lymphoma: Lower Risk After Smaller Radiation Volumes

C. Lawton, 2010 .

Natural History of Clinically Staged Low- and Intermediate-Risk Prostate Cancer Treated With Monotherapeutic Permanent Interstitial Brachytherapy

C. Lawton, 2011 .

Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.

D. Grignon, K. Bae, J. Speight, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials.

D. Grignon, W. Shipley, J. Cox, 2000, International journal of radiation oncology, biology, physics.

Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: Recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009)

C. Lawton, 2011 .

Radiation dose–volume effects in radiation-induced rectal injury

C. Lawton, 2011 .

Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung.

R. Komaki, W. Sause, B. Emami, 1998, International journal of radiation oncology, biology, physics.

Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis: A Randomized Clinical Trial

C. Lawton, 2012 .

Association of Occult Metastases in Sentinel Lymph Nodes and Bone Marrow With Survival Among Women With Early-Stage Invasive Breast Cancer

C. Lawton, 2012 .

Prostate cancer: are racial differences in clinical stage and survival explained by differences in symptoms?

C. Lawton, R. Byhardt, J. Wilson, 1994, Radiology.

Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer: Results of the Phase III Trial ACCORD 12/0405-Prodige 2

C. Lawton, 2011 .

Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial

C. Lawton, 2012 .

Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis.

A. Kishan, R. Mehra, H. Sandler, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma

C. Lawton, 2011 .

VA-Radiation Oncology Quality Surveillance Program.

L. Potters, I. Chetty, J. DeMarco, 2020, International journal of radiation oncology, biology, physics.

Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial

C. Lawton, 2010 .

Duration of Androgen Suppression in the Treatment of Prostate Cancer

C. Lawton, 2010 .

Effect of Obesity on Prognosis After Early-Stage Breast Cancer

C. Lawton, 2012 .

Local Excision Alone Without Irradiation for Ductal Carcinoma In Situ of the Breast: A Trial of the Eastern Cooperative Oncology Group

C. Lawton, C. A. Lawton, 2010 .

Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer

C. Lawton, 2011 .

Active Surveillance Compared With Initial Treatment for Men With Low-Risk Prostate Cancer: A Decision Analysis

C. Lawton, 2011 .

Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. Hanks GE, Pajak TF, Porter A, Grignon

C. Lawton, Shi-xiu Wu, 2004 .

Is long‐term survival possible with external beam irradiation for stage D1 adenocarcinoma of the prostate?

J. Cox, C. Lawton, R. Byhardt, 1992, Cancer.

Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer

C. Lawton, 2011 .

Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer

C. Lawton, 2011 .

RTOG's first quality of life study--RTOG 90-20: a phase II trial of external beam radiation with etanidazole for locally advanced prostate cancer.

D. Cella, C. Beard, C. Scott, 1995, International journal of radiation oncology, biology, physics.

Does hormone therapy reduce disease recurrence in prostate cancer patients receiving dose-escalated radiation therapy? An analysis of Radiation Therapy Oncology Group 94-06

C. Lawton, 2012 .

[Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials].

D. Grignon, W. Shipley, J. Cox, 2001 .

Radiotherapy and Short-Term Androgen Deprivation for Localized Prostate Cancer

C. Lawton, 2012 .

Cardiovascular Mortality After Androgen Deprivation Therapy for Locally Advanced Prostate Cancer: RTOG 85-31

C. Lawton, 2010 .

Quality of life outcomes from a dose-per-fraction escalation trial of hypofractionation in prostate cancer.

D. Petereit, M. Ritter, J. Forman, 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Reply to S. Sundar et al and S. Höcht et al.

C. Lawton, Soumyajit Roy, Daniel E Spratt, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A national propensity-adjusted analysis of adjuvant radiotherapy in the treatment of resected pancreatic adenocarcinoma

C. Lawton, 2011 .

Lack of Comprehension of Common Prostate Cancer Terms in an Underserved Population

C. Lawton, 2010 .

Endocrine treatment with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomized phase III trial

C. Lawton, 2010 .

Management of Seminomatous Testicular Cancer: A Binational Prospective Population-Based Study From the Swedish Norwegian Testicular Cancer Study Group

C. Lawton, 2012 .

Randomized Trial of Carboplatin Versus Radiotherapy for Stage I Seminoma: Mature Results on Relapse and Contralateral Testis Cancer Rates in MRC TE19/EORTC 30982 Study (ISRCTN27163214)

C. Lawton, 2012 .

Obesity and Mortality in Men With Locally Advanced Prostate Cancer: Analysis of RTOG 85-31

C. Lawton, 2009 .

Recombinant Human Interferon-β (rHuIFN-β) and Radiation Therapy for Inoperable Non-Small Cell Lung Cancer

E. Borden, L. Vaickus, C. Lawton, 1996 .

American College of Radiology Appropriateness Criteria® on Conservative Surgery and Radiation: Stages I and II Breast Carcinoma

C. Lawton, 2009 .

Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis: A Randomized Clinical Trial

C. Lawton, 2012 .

A Multicenter Randomized Trial of Breast Intensity-Modulated Radiation Therapy to Reduce Acute Radiation Dermatitis

C. Lawton, 2009 .

Late Rectal Complications After Prostate Brachytherapy for Localized Prostate Cancer: Incidence and Management

C. Lawton, 2010 .

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

C. Lawton, 2011 .

Evaluation of late adverse events in long-term Wilms' tumor survivors

C. Lawton, 2011 .

Ten-Year Follow-up of Radiation Therapy Oncology Group Protocol 92-02: A Phase III Trial of the Duration of Elective Androgen Deprivation in Locally Advanced Prostate Cancer

C. Lawton, 2009 .

Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO)

C. Lawton, 2010 .

Quality assurance methods for the first Radiation Therapy Oncology Group permanent prostate implant protocol.

G. Ibbott, J. Michalski, M. Gillin, 2006, Brachytherapy.

Extended‐Field Radiation Therapy for Prostatic Carcinoma with Para‐Aortic Lymph Node Metastasis

J. Cox, A. Hartz, C. Glisch, 1986, American journal of clinical oncology.

Evaluation of nuclear factor κB and chemokine receptor CXCR4 co‐expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610

H. Sandler, Liang Cheng, A. Dicker, 2011, BJU international.

Racial Differences in Treatment and Outcomes Among Patients With Early Stage Bladder Cancer

C. Lawton, 2011 .

A Prospective Multi-institutional Phase I/II Trial of Step-wise Dose-per-Fraction Escalation in Low and Intermediate Risk Prostate Cancer.

D. Petereit, M. Ritter, J. Forman, 2020, Practical radiation oncology.

Impact of the Duration of Adjuvant Hormonal Therapy in Patients With Locally Advanced Prostate Cancer Treated With Radiotherapy: A Secondary Analysis of RTOG 85-31

C. Lawton, 2010 .

Malignant Gliomas in Adults

C. Lawton, 2009 .

Vitamin E and the Risk of Prostate Cancer: The Selenium and Vitamin E Cancer Prevention Trial (SELECT)

C. Lawton, C. Lawton, 2012 .

Phase III trial of hormonal cytoreduction in conjunction with definitive radiotherapy in locally advanced prostate carcinoma: the emerging role of psa in the assessment of outcome

R. Abrams, P. Rubin, W. Sause, 1993 .

NRG Oncology/RTOG 9601, a phase III trial in prostate cancer patients: Anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following radical prostatectomy (RP) and an elevated PSA.

D. Grignon, A. Zietman, H. Sandler, 2016 .

Patient reported outcomes in NRG Oncology/RTOG 0938, evaluating two ultrahypofractionated regimens (UHR) for prostate cancer (CaP).

I. Kaplan, D. Beyer, H. Sandler, 2016 .

Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer

C. Lawton, 2011 .

Screening and Prostate-Cancer Mortality in a Randomized European Study

C. Lawton, C. A. Lawton, 2010 .

Oncologic control provided by HIFU therapy as single treatment in men with clinically localized prostate cancer

C. Lawton, 2009 .

A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117

C. Lawton, 2011 .

Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline.

K. Hoffman, H. Sandler, J. Efstathiou, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02.

M. Hammond, H. Sandler, M. Desilvio, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer

D. Grignon, A. Zietman, H. Sandler, 2017, The New England journal of medicine.

Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.

D. Grignon, P. Rubin, W. Sause, 2001, International journal of radiation oncology, biology, physics.

Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer

C. Lawton, C. Lawton, 2012 .

Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women

C. Lawton, 2010 .

Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31.

D. Grignon, W. Shipley, G. Hanks, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group.

R. Abrams, P. Rubin, W. Sause, 1995, Urology.

Prostate‐specific antigen response after short‐term hormone therapy plus external‐beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413

I. Hsu, H. Sandler, M. Roach, 2013, Cancer.

D. Grignon, T. Pajak, H. Sandler, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413.

R K Valicenti, M Machtay, C. Jones, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of biochemical failure classification on clinical outcome: A secondary analysis of Radiation Therapy Oncology Group 9202 and 9413

H. Sandler, K. Bae, W. Shipley, 2015, Cancer.

Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: an analysis of RTOG 8610.

D. Grignon, R. Abrams, K. Fu, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant radiation therapy, androgen deprivation, and docetaxel for high‐risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621

K. Badiozamani, D. Beyer, H. Sandler, 2017, Cancer.

Chapter 53 – Prostate Cancer

L. Potters, T. Pisansky, J. Michalski, 2016 .

Practice-based evidence to evidence-based practice: building the National Radiation Oncology Registry.

L. Potters, K. Hoffman, A. Zietman, 2013, Journal of oncology practice.

The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies.

W. Sause, B. Movsas, J. Cox, 1999, International journal of radiation oncology, biology, physics.

Phase III Comparison of Prophylactic Cranial Irradiation Versus Observation in Patients With Locally Advanced Non–Small-Cell Lung Cancer: Primary Analysis of Radiation Therapy Oncology Group Study RTOG 0214

C. Lawton, 2012 .

Metabolic Changes During Gonadotropin-releasing Hormone Agonist Therapy For Prostate Cancer: Differences From the Classic Metabolic Syndrome

C. Lawton, 2009 .

Long-Term Outcomes in Younger Men Following Permanent Prostate Brachytherapy

C. Lawton, 2010 .

Exposure to Oral Bisphosphonates and Risk of Esophageal Cancer

C. Lawton, 2011 .

2222 Variation in the Definition of Clinical Target Volumes for Postoperative Conformal Radiation Therapy of

C. Catton, H. Sandler, M. Ritter, 2007 .

Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer.

D. Grignon, H. Sandler, K. Bae, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association Between Hospital and Surgeon Radical Prostatectomy Volume and Patient Outcomes: A Systematic Review

C. Lawton, 2009 .

Randomized Trial Comparing Conventional-Dose With High-Dose Conformal Radiation Therapy in Early-Stage Adenocarcinoma of the Prostate: Long-Term Results From Proton Radiation Oncology Group/American College of Radiology 95-09

C. Lawton, Colleen A. Lawton, 2011 .

Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer

C. Lawton, Colleen A. Lawton, 2009 .

Effect of Occult Metastases on Survival in Node-Negative Breast Cancer

C. Lawton, 2012 .

Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analy

C. Lawton, 2010 .

Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer

C. Lawton, 2012 .

The Future of Radiation Oncology: The Evolution Diversification and Survival of the Specialty

C. Lawton, 2009 .

Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial

C. Lawton, C. A. Lawton, 2010 .

Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial

C. Lawton, 2012 .

Effect of Dutasteride on the Risk of Prostate Cancer

C. Lawton, 2011 .

Assessment of extended-field radiotherapy for stage IIIC endometrial cancer using three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, and helical tomotherapy

C. Lawton, 2009 .

Lung cancer in ‘Never-smokers’: a unique entity

C. Lawton, 2011 .

Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202.

D. Grignon, H. Sandler, H. Lepor, 2015, International journal of radiation oncology, biology, physics.

Ten-Year Follow-Up of 3 Years of Oral Adjuvant Clodronate Therapy Shows Significant Prevention of Osteoporosis in Early-Stage Breast Cancer

C. Lawton, 2009 .

Variations in Quality of Care for Men With Early-Stage Prostate Cancer

C. Lawton, 2009 .

Title Duration of Androgen Deprivation in Locally Advanced Prostate Cancer : Long-Term

D. Grignon, H. Lepor, T. Pisansky, 2017 .

Risk factors for late bowel and bladder toxicities in NRG Oncology prostate cancer trials of high-risk patients: A meta-analysis of physician-rated toxicities

I. Hsu, E. Horwitz, D. D'Souza, 2018, Advances in radiation oncology.

Phase I II T rial C omparing W hole-Pelvic V ersus P rostate-Only Radiotherapy a nd N eoadjuvant V ersus A djuvant C ombined Androgen S uppression: R adiation T herapy O ncology Group 9 413

C. Jones, M. Desilvio, M. Roach, 2003 .

Randomized Trial of a Hypnosis Intervention for Treatment of Hot Flashes Among Breast Cancer Survivors

C. Lawton, 2009 .

Late outcomes following hypofractionated conformal radiotherapy vs. standard fractionation for localized prostate cancer: a nonrandomized contemporary comparison

C. Lawton, 2010 .

Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer

C. Lawton, 2009 .

Short-Term Neoadjuvant Androgen Deprivation Therapy and External-Beam Radiotherapy for Locally Advanced Prostate Cancer: Long-Term Results of RTOG 8610

C. Lawton, 2009 .

Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I125 prostate brachytherapy in clinically localized prostate cancers: Seattle experience

C. Lawton, 2012 .

Report of NRG Oncology/RTOG 9601, A Phase 3 Trial in Prostate Cancer: Anti-androgen Therapy (AAT) With Bicalutamide During and After Radiation Therapy (RT) in Patients Following Radical Prostatectomy (RP) With pT2-3pN0 Disease and an Elevated PSA

D. Grignon, A. Zietman, H. Sandler, 2016 .

Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer

C. Lawton, 2011 .

Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No

C. Lawton, 2009 .

Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen

Charles R. Thomas, C. Lawton, S. Han, 2003 .

Randomized comparison of whole brain radiotherapy, 20Gy in four daily fractions versus 40Gy in 20 twice-daily fractions, for brain metastases

C. Lawton, 2011 .

RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer.

C. Ménard, M. Ritter, J. Michalski, 2009, International journal of radiation oncology, biology, physics.

Variation in the definition of clinical target volumes for pelvic nodal conformal radiation therapy for prostate cancer.

Issam El-Naqa, Mack Roach, Charles Catton, 2007, International journal of radiation oncology, biology, physics.

Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial

C. Lawton, 2010 .

Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31). Radiation Therapy Oncology Group.

W. Sause, G. Hanks, M. Rotman, 1998, International journal of radiation oncology, biology, physics.

Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706.

P. Rubin, S. Doggett, W. Sause, 1991, International journal of radiation oncology, biology, physics.

Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate.

H. Sandler, M. Kuettel, J. Crook, 2010, International journal of radiation oncology, biology, physics.

Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline.

K. Hoffman, H. Sandler, J. Efstathiou, 2018, The Journal of urology.

Significance of Tertiary Gleason Pattern 5 in Gleason Score 7 Radical Prostatectomy Specimens

C. Lawton, 2009 .

Bladder-sparing, Combined-modality Approach for Muscle-invasive Bladder Cancer: A Multi-institutional, Long-term Experience

C. Lawton, 2009 .

Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer

C. Lawton, 2010 .

Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening

C. Lawton, 2012 .

Active Surveillance Compared With Initial Treatment for Men With Low-Risk Prostate Cancer: A Decision Analysis

C. Lawton, 2011 .

Active Surveillance Compared With Initial Treatment for Men With Low-Risk Prostate Cancer: A Decision Analysis

C. Lawton, G. Lu-Yao, 2011 .

Early Postoperative Plasma Transforming Growth Factor-β1 is a Strong Predictor of Biochemical Progression After Radical Prostatectomy

C. Lawton, 2009 .

Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer

C. Lawton, 2011 .

A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or 125I permanent implant

C. Lawton, 2009 .

The effect of intensity-modulated radiotherapy on radiation-induced second malignancies

C. Lawton, C. A. Lawton, 2009 .